皮秒翠绿宝石激光治疗儿童获得性双侧奥塔样斑痣的回顾性研究。

IF 2.2 3区医学 Q2 DERMATOLOGY

Lasers in Surgery and Medicine Pub Date : 2025-04-29 DOI:10.1002/lsm.70021

Wenwen Zhao, Hedan Yang, Xing liu, Wanting Jiang, Sanjing Chen, Tong Lin, Yiping Ge, Yan Zong

{"title":"皮秒翠绿宝石激光治疗儿童获得性双侧奥塔样斑痣的回顾性研究。","authors":"Wenwen Zhao, Hedan Yang, Xing liu, Wanting Jiang, Sanjing Chen, Tong Lin, Yiping Ge, Yan Zong","doi":"10.1002/lsm.70021","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Picosecond lasers have been increasingly applied to the treatment of acquired bilateral nevus of Ota-like macules (ABNOMs), and proved safe and effective for adult patients. But there has been limited data concerned with their use in children.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To analyze the efficacy, safety, and correlative influencing factors of a 755 nm picosecond alexandrite laser in treating ABNOMs in children.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We retrospectively analyzed children with ABNOMs from January 2017 to July 2023 who received the treatment using a 755 nm picosecond alexandrite laser. Treatment parameters used were as follows: 750 ps pulse duration, 2.34–4.07 J/cm² fluence, and 2.5–3.3 mm spot size. The mean treatment interval was 7 months. The efficacy was evaluated based on a five-point scale according to the percentage of pigmentation clearance.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 49 pediatric patients were included in this retrospective study. The average age at the beginning of treatment was 16.87 months old (range of 4 months to 59 months). These patients received an average of two treatments, achieving an average of 76% pigment clearance, which corresponded to excellent improvement (75%–94%). After the first treatment, six cases reached clinical clearance, and an average of pigment clearance was 61%. The initial efficacy was positively correlated with Fitzpatrick type (<i>p</i> < 0.05). Patients with Fitzpatrick III skin type responded better than patients with Fitzpatrick IV skin type. Besides, the initial efficacy was negatively correlated with the first treatment age and disease duration (<i>p</i> < 0.05). Eight cases developed postinflammatory hyperpigmentation, accounting for 16.3% of the cases.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The 755 nm picosecond alexandrite laser is safe and effective in treating ABNOMs in children. Being younger at the initial treatment, having Fitzpatrick III skin type, and experiencing a shorter disease duration are beneficial for initial efficacy.</p>\n </section>\n </div>","PeriodicalId":17961,"journal":{"name":"Lasers in Surgery and Medicine","volume":"57 5","pages":"359-364"},"PeriodicalIF":2.2000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Retrospective Study of Picosecond Alexandrite Laser Treatment for Acquired Bilateral Nevus of Ota-Like Macules in Children\",\"authors\":\"Wenwen Zhao, Hedan Yang, Xing liu, Wanting Jiang, Sanjing Chen, Tong Lin, Yiping Ge, Yan Zong\",\"doi\":\"10.1002/lsm.70021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Picosecond lasers have been increasingly applied to the treatment of acquired bilateral nevus of Ota-like macules (ABNOMs), and proved safe and effective for adult patients. But there has been limited data concerned with their use in children.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To analyze the efficacy, safety, and correlative influencing factors of a 755 nm picosecond alexandrite laser in treating ABNOMs in children.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We retrospectively analyzed children with ABNOMs from January 2017 to July 2023 who received the treatment using a 755 nm picosecond alexandrite laser. Treatment parameters used were as follows: 750 ps pulse duration, 2.34–4.07 J/cm² fluence, and 2.5–3.3 mm spot size. The mean treatment interval was 7 months. The efficacy was evaluated based on a five-point scale according to the percentage of pigmentation clearance.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 49 pediatric patients were included in this retrospective study. The average age at the beginning of treatment was 16.87 months old (range of 4 months to 59 months). These patients received an average of two treatments, achieving an average of 76% pigment clearance, which corresponded to excellent improvement (75%–94%). After the first treatment, six cases reached clinical clearance, and an average of pigment clearance was 61%. The initial efficacy was positively correlated with Fitzpatrick type (<i>p</i> < 0.05). Patients with Fitzpatrick III skin type responded better than patients with Fitzpatrick IV skin type. Besides, the initial efficacy was negatively correlated with the first treatment age and disease duration (<i>p</i> < 0.05). Eight cases developed postinflammatory hyperpigmentation, accounting for 16.3% of the cases.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The 755 nm picosecond alexandrite laser is safe and effective in treating ABNOMs in children. Being younger at the initial treatment, having Fitzpatrick III skin type, and experiencing a shorter disease duration are beneficial for initial efficacy.</p>\\n </section>\\n </div>\",\"PeriodicalId\":17961,\"journal\":{\"name\":\"Lasers in Surgery and Medicine\",\"volume\":\"57 5\",\"pages\":\"359-364\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lasers in Surgery and Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/lsm.70021\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lasers in Surgery and Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/lsm.70021","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：皮秒激光越来越多地应用于获得性双侧奥塔样斑痣（ABNOMs）的治疗，并且被证明对成人患者安全有效。但是，关于儿童使用它们的数据有限。目的：分析755 nm皮秒紫翠绿宝石激光治疗儿童ABNOMs的疗效、安全性及相关影响因素。方法：回顾性分析2017年1月至2023年7月接受755 nm皮秒亚历山大变石激光治疗的ABNOMs患儿。使用的处理参数如下：750 ps脉冲持续时间，2.34-4.07 J/cm²通量，2.5-3.3 mm光斑尺寸。平均治疗间隔为7个月。根据色素沉着清除的百分比，以五分制评估疗效。结果：本回顾性研究共纳入49例儿科患者。治疗开始时平均年龄16.87个月（4 ~ 59个月）。这些患者平均接受两次治疗，平均达到76%的色素清除率，这相当于优异的改善（75%-94%）。第一次治疗后，6例达到临床清除率，平均色素清除率为61%。结论：755 nm皮秒翠绿宝石激光治疗儿童ABNOMs安全有效。初始治疗时较年轻、Fitzpatrick III型皮肤、病程较短有利于初始疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Retrospective Study of Picosecond Alexandrite Laser Treatment for Acquired Bilateral Nevus of Ota-Like Macules in Children

Background

Picosecond lasers have been increasingly applied to the treatment of acquired bilateral nevus of Ota-like macules (ABNOMs), and proved safe and effective for adult patients. But there has been limited data concerned with their use in children.

Objective

To analyze the efficacy, safety, and correlative influencing factors of a 755 nm picosecond alexandrite laser in treating ABNOMs in children.

Methods

We retrospectively analyzed children with ABNOMs from January 2017 to July 2023 who received the treatment using a 755 nm picosecond alexandrite laser. Treatment parameters used were as follows: 750 ps pulse duration, 2.34–4.07 J/cm² fluence, and 2.5–3.3 mm spot size. The mean treatment interval was 7 months. The efficacy was evaluated based on a five-point scale according to the percentage of pigmentation clearance.

Results

A total of 49 pediatric patients were included in this retrospective study. The average age at the beginning of treatment was 16.87 months old (range of 4 months to 59 months). These patients received an average of two treatments, achieving an average of 76% pigment clearance, which corresponded to excellent improvement (75%–94%). After the first treatment, six cases reached clinical clearance, and an average of pigment clearance was 61%. The initial efficacy was positively correlated with Fitzpatrick type (p < 0.05). Patients with Fitzpatrick III skin type responded better than patients with Fitzpatrick IV skin type. Besides, the initial efficacy was negatively correlated with the first treatment age and disease duration (p < 0.05). Eight cases developed postinflammatory hyperpigmentation, accounting for 16.3% of the cases.

Conclusion

The 755 nm picosecond alexandrite laser is safe and effective in treating ABNOMs in children. Being younger at the initial treatment, having Fitzpatrick III skin type, and experiencing a shorter disease duration are beneficial for initial efficacy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lasers in Surgery and Medicine 医学-外科

CiteScore

5.40

自引率

12.50%

发文量

119

审稿时长

1 months

期刊介绍： Lasers in Surgery and Medicine publishes the highest quality research and clinical manuscripts in areas relating to the use of lasers in medicine and biology. The journal publishes basic and clinical studies on the therapeutic and diagnostic use of lasers in all the surgical and medical specialties. Contributions regarding clinical trials, new therapeutic techniques or instrumentation, laser biophysics and bioengineering, photobiology and photochemistry, outcomes research, cost-effectiveness, and other aspects of biomedicine are welcome. Using a process of rigorous yet rapid review of submitted manuscripts, findings of high scientific and medical interest are published with a minimum delay.